-
- Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
by GRACE Video on Jun 19, 2013 in GRACE :: Lung Cancer
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
[powerpress]
>> Discuss this G... (Read More)
- Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
by GRACE Video on Jun 18, 2013 in GRACE :: Lung Cancer
Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.
[powerpress]... (Read More)
- Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?
by GRACE Video on Jun 17, 2013 in GRACE :: Lung Cancer
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the POINTBREAK trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
[powerpress]
... (Read More)
- Do you need Avastin in first line and maintenance therapy in advanced NSCLC?
by GRACE Video on Jun 14, 2013 in GRACE :: Lung Cancer
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
[powerpress]
>> Discuss this ... (Read More)
- Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
by GRACE Video on Jun 13, 2013 in GRACE :: Lung Cancer
Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
[powerpress]... (Read More)
- Can we predict which patients will benefit from Tarceva based on a blood test?
by GRACE Video on Jun 12, 2013 in GRACE :: Lung Cancer
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
[powerpress]
... (Read More)
- Drs. Ross Camidge and Corey Langer: How Do You Make Use of a Broad Molecular Profile Brought by a Patient?
by GRACE Video on Jun 11, 2013 in GRACE :: Lung Cancer
Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.
[powerpress]... (Read More)
- Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?
by GRACE Video on Jun 10, 2013 in GRACE :: Lung Cancer
Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).
[powerpress]... (Read More)
- Is it possible to test for biomarkers in lung cancer on a national scale?
by Dr West on Jun 8, 2013 in GRACE :: Lung Cancer
This is the first video in our series from a program filmed directly from ASCO 2013. Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung canc... (Read More)
- Direct From ASCO: Highlights & New Approaches
by GRACE Video on Jun 7, 2013 in GRACE :: Lung Cancer
Drs. Nate Pennell from Cleveland Clinic and Mary Pinder from Moffitt Cancer Center in Tampa, FL sat down with our own Dr. Jack West to discuss early impressions of some of the most provocative research presented at the American Society for Clinical Oncology (ASCO) Annua... (Read More)
